• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Novartis - Articles and news items

NIH study shows Novartis drug eltrombopag improves responses in severe aplastic anemia

Industry news / 20 April 2017 / Niamh Marriott, Junior Editor

Novartis demonstrated that 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved complete response at six months when treated…

Novartis expands development programs for NASH with Allergan clinical partnership

Industry news / 20 April 2017 / Niamh Marriott, Junior Editor

Novartis has entered into a clinical trial agreement with Allergan to conduct a Phase IIb study, involving the combination of a Novartis’ FXR agonist…

Novartis’ lymphoma treatment receives FDA breakthrough therapy designation

Industry news / 19 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies. This is the second indication for which […]

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

Novartis’ lung cancer drug combination receives EU approval

Industry news / 5 April 2017 / Niamh Marriott, Junior Editor

The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat fnon-small cell lung cancer…

skin

Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause

Industry news / 15 March 2017 / Niamh Marriott, Junior Editor

Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause…

Sandoz biosimilar adalimumab study shows equivalent efficacy

Industry news / 14 March 2017 / Niamh Marriott, Junior Editor

Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab, GP2017, showing that their Phase III study met its primary endpoint…

Novartis receives positive CHMP opinion for lung cancer combination

Industry news / 27 February 2017 / Niamh Marriott, Digital Editor

The EMA approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with non-small cell lung cancer…

Nanobiotix appoints Oncology industry veteran as Chief Operating Officer

Industry news / 7 February 2017 / Niamh Marriott, Digital Editor

Nanobiotix, a late clinical-stage nanomedicine company, announced the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer. Mr Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for their lead product NBTXR3, which could obtain a CE Mark approval in 2017. Previously, Mr Dostie was […]

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

Cardiovascular risk

Novartis invests in Ionis’ therapies to reduce cardiovascular risk

Industry news / 10 January 2017 / Niamh Marriott, Digital Editor

Novartis announced a collaboration and option agreement to license two novel treatments with the potential to significantly reduce cardiovascular risk…

macular degeneration

Novartis’ macular degeneration Phase III trial did not meet endpoint

Industry news / 14 December 2016 / Niamh Louise Marriott, Digital Editor

Novartis’ two pivotal Phase III clinical studies did not meet their primary endpoints to treatment of neovascular age-related macular degeneration…